weight loss drugs non glp 1 Losing the Meds Audiobook by Holly R. Wyatt MD, James O. Hill PhD The Boom in New Weight

Conclusions In summary, the results of this large active comparator, new user cohort study indicate that GLP-1 receptor agonists are not associated with an increased risk of suicidal ideation, self-harm, and suicide when compared with DPP-4 inhibitors or SGLT-2 inhibitors among patients with type 2 diabetes

10 Nonetheless, any new diabetes drug must still demonstrate safety concerning cardiovascular outcomes, and many new agents continue to undergo cardiovascular outcomes trials to meet these standards

- **Curb appetite:** Helping individuals feel full, potentially leading to reduced food intake

Liu J, Yin F, Xiao H, Guo L, Gao X

Power, E

Live casinos remain a centerpiece, combining the social energy of a studio with the reliability of digital interfaces